Meghan Podolsky
meg-po.bsky.social
Meghan Podolsky
@meg-po.bsky.social
Research Fellow, Real World Data Research @ BMS | BUSPH
Chronic disease epidemiology, health services research, & HEOR

https://www.linkedin.com/in/meghan-podolsky-099b23145
Pinned
What factors affect semaglutide prescription?

In our study in @JAMANetworkOpen, we found that sex, insurance plan type, and use of certain medications were associated with semaglutide initiation.

jamanetwork.com/journals/jaman…
1/
https://jamanetwork.com/journals/jaman…
Reposted by Meghan Podolsky
This right question about prevention: not whether it saves money, but whether it is worth the cost.

tinyurl.com/3ezrrvm4 @tuftscevr.bsky.social #health #prevention
Can Prevention Save Money?
This JAMA Forum discusses some key considerations for addressing the question of whether and when prevention interventions are worth the cost.
tinyurl.com
April 7, 2025 at 9:03 PM
Reposted by Meghan Podolsky
Don't miss a chance to work with our renowned faculty! Applications for our 2025 CEA Registry Summer Fellowship close March 17th.

Learn more / apply today: cevr.tuftsmedicalcenter.org/news/2025-ce...

#internships #fellowship #healthecon

@pattysynnott.bsky.social @peterneumann11.bsky.social
2025 CEA Registry Remote Fellowship - Center for the Evaluation of Value and Risk in Health
cevr.tuftsmedicalcenter.org
February 17, 2025 at 4:55 PM
Reposted by Meghan Podolsky
Most viewed in the last 7 days from JAMA: This Medical News article discusses how the popularity of the antiobesity drugs #semaglutide and #tirzepatide may affect uptake of bariatric surgery.

https://ja.ma/4hLUcWf
February 8, 2025 at 12:00 PM
Reposted by Meghan Podolsky
Insurance type and employment sector significantly influence access to semaglutide for weight management, highlighting disparities in healthcare access for obesity treatment. doi.org/g82s48
Insurance coverage and type of employment shape inequities in access to semaglutide
Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity since the US Food & Drug Administration first approved semaglutide (brand name Ozempic/Wegovy) for weight loss in 2021.
medicalxpress.com
January 23, 2025 at 6:02 AM
Insurance Coverage, Type of Employment Shape Inequities in Access to Semaglutide @busph.bsky.social bu.edu/sph/news/artic…#obesityt#healthequityt#publichealtht#glp1p#semaglutidede
https://bu.edu/sph/news/artic…
January 22, 2025 at 5:40 PM
What factors affect semaglutide prescription?

In our study in @JAMANetworkOpen, we found that sex, insurance plan type, and use of certain medications were associated with semaglutide initiation.

jamanetwork.com/journals/jaman…
1/
https://jamanetwork.com/journals/jaman…
January 21, 2025 at 4:33 PM
Reposted by Meghan Podolsky
New data on baseline levels of treatment for obesity pre-GLP1s - TLDR - very low journals.lww.com/lww-medicalc...
Trends in Obesity Care Among US Adults, 2010–2021 : Medical Care
th obesity care from 2010 to 2021 in the United States. Research Design: This multiyear cross-sectional study was conducted using Medical Expenditure Panel Survey (MEPS) data, covering respondents ...
journals.lww.com
January 17, 2025 at 7:19 PM